

Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
You can purchase shares of Ascendis Pharma (NASDAQ:ASND) through any online brokerage.
Other companies in Ascendis Pharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Ascendis Pharma has a consensus price target of $299.08.
The stock price for Ascendis Pharma (NASDAQ: ASND) is $250.17 last updated November 3, 2026 at 4:24 PM EST.
There are no upcoming dividends for Ascendis Pharma.
Ascendis Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for Ascendis Pharma.
Ascendis Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP,...